Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, Inc. : Increase of volatility

07/28/2020 | 09:24am EDT
long trade
Stop-loss triggered
Entry price : 38.54$ | Target : 43.9$ | Stop-loss : 34.4$ | Potential : 13.91%
Pfizer, Inc. shares have been in strong demand lately. The technical chart pattern looks positive which may give rise to new gains.
Investors have an opportunity to buy the stock and target the $ 43.9.
Pfizer, Inc. : Pfizer, Inc. : Increase of volatility
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 40.51.
  • Technically, the stock approaches a strong medium-term resistance at USD 38.56.
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The group usually releases earnings worse than estimated.
  • With an enterprise value anticipated at 4.97 times the sales for the current fiscal year, the company turns out to be overvalued.

ę MarketScreener.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 79 586 M - -
Net income 2021 18 722 M - -
Net Debt 2021 26 885 M - -
P/E ratio 2021 13,1x
Yield 2021 3,49%
Capitalization 253 B 253 B -
EV / Sales 2021 3,52x
EV / Sales 2022 4,25x
Nbr of Employees 78 500
Free-Float 59,2%
Upcoming event on PFIZER, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Last Close Price 45,19 $
Average target price 43,82 $
Spread / Average Target -3,03%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.22.77%252 960
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
ELI LILLY AND COMPANY55.45%237 950
NOVARTIS AG-0.36%223 613
NOVO NORDISK A/S43.21%222 926